Akkermansia muciniphila: Paradigm for next-generation beneficial microorganisms

Patrice D. Cani*, Clara Depommier, Muriel Derrien, Amandine Everard, Willem M. de Vos

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

118 Citations (Scopus)


Ever since Akkermansia muciniphila was discovered and characterized two decades ago, numerous studies have shown that the lack or decreased abundance of this commensal bacterium was linked with multiple diseases (such as obesity, diabetes, liver steatosis, inflammation and response to cancer immunotherapies). Although primarily based on simple associations, there are nowadays an increasing number of studies moving from correlations to causality. The causal evidence derived from a variety of animal models performed in different laboratories and recently was also recapitulated in a human proof-of-concept trial. In this Review, we cover the history of the discovery of A. muciniphila and summarize the numerous findings and main mechanisms of action by which this intestinal symbiont improves health. A comparison of this microorganism with other next-generation beneficial microorganisms that are being developed is also made.

Original languageEnglish
Pages (from-to)625-637
JournalNature Reviews Gastroenterology and Hepatology
Issue number10
Early online date31 May 2022
Publication statusPublished - Oct 2022


Dive into the research topics of 'Akkermansia muciniphila: Paradigm for next-generation beneficial microorganisms'. Together they form a unique fingerprint.

Cite this